REGEIVED
CENTRAL FAX CENTER
MAY 0.9 2008

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- 1. (Currently Amended) A composition suitable for <u>oral</u> administration to an animal for the purpose of sequestering one or more lipophilic materials present in the gastrointestinal tract of the animal, wherein the composition comprises a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a high internal phase emulsion foam; and wherein said composition is selected from the group consisting of capsule, pill, caplet, tablet, chewable tablet, suspension, suppository, and combinations thereof.
- 2. (Original) The composition according to Claim 1 wherein the foam has a density of less than about 0.1 g/cc.
- 3. (Original)The composition according to Claim 2 wherein the foam comprises a component selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acctate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof.
- 4. (Canceled).
- 5. (Previously Amended) The composition according to Claim 1, wherein the HIPE foam is characterized by the following:
 - (a) a specific surface area per foam volume of at least about 0.01 m²/cc; and
 - (b) a glass transition temperature (Tg) from about -40°C to about 90°C.

Page 2 of 8

- 6. (Original)The composition according to Claim 1 further comprising a lipase inhibitor.
- 7. (Canceled).
- 8. (Previously Amended) The composition according to Claim 6, wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
- 9. (Original)The composition according to Claim 8 wherein at least one of the lipase inhibitors is a compound having the structure:

wherein A is the group

or --(CH2)5--

10-22. (Canceled)

- 23. (Currently Amended) A kit comprising:
 - (a) a first composition <u>suitable for oral</u> administration comprising a non-digestible, non-absorbable, open-celled polymeric foam; and

Page 3 of 8

- (b) a second composition comprising a component selected from the group consisting of vitamins, lipase inhibitors, laxatives, and combinations thereof: and wherein the foam is a HIPE foam.
- 24. (Canceled)
- 25. (Original) The kit according to Claim 23 wherein the second composition comprises a lipase inhibitor selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
- 26. (Original) The kit according to Claim 25 wherein the lipase inhibitor is a compound having the structure:

wherein A is the group

or -- (CH2)5-

- 27. (Currently Amended) A kit comprising:
 - (a) a composition suitable for oral administration comprising a non-digestible, non-absorbable, open-celled polymeric foam; and
 - (b) information associated with the composition that use of the composition will provide one or more benefits selected from the group consisting of sequestration of

Page 4 of 8

lipophlic materials, treatment of gastrointestinal distress, treatment of fecal urgency, treatment of obesity, weight loss, weight control, treatment of hyperlipidemia, treatment of diarrhea, inhibition of anal leakage, reduction of levels of toxic substances, treatment of Type II Diabetes, delay of onset of Type II Diabetes, prevention of Type II Diabetes, and combinations thereof; wherein the foam is a HIPE foam.

28. (Canceled).